250 related articles for article (PubMed ID: 21111666)
1. The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer.
Vandercappellen J; Van Damme J; Struyf S
Cytokine Growth Factor Rev; 2011 Feb; 22(1):1-18. PubMed ID: 21111666
[TBL] [Abstract][Full Text] [Related]
2. The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo.
Vandercappellen J; Liekens S; Bronckaers A; Noppen S; Ronsse I; Dillen C; Belleri M; Mitola S; Proost P; Presta M; Struyf S; Van Damme J
Mol Cancer Res; 2010 Mar; 8(3):322-34. PubMed ID: 20215425
[TBL] [Abstract][Full Text] [Related]
3. Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis.
Struyf S; Burdick MD; Peeters E; Van den Broeck K; Dillen C; Proost P; Van Damme J; Strieter RM
Cancer Res; 2007 Jun; 67(12):5940-8. PubMed ID: 17575164
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of angiostatic platelet factor-4 variant (CXCL4L1/PF-4var) versus inhibition of angiogenic granulocyte chemotactic protein-2 (CXCL6/GCP-2) in normal and tumoral mesenchymal cells.
Vandercappellen J; Noppen S; Verbeke H; Put W; Conings R; Gouwy M; Schutyser E; Proost P; Sciot R; Geboes K; Opdenakker G; Van Damme J; Struyf S
J Leukoc Biol; 2007 Dec; 82(6):1519-30. PubMed ID: 17827342
[TBL] [Abstract][Full Text] [Related]
5. Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis.
Struyf S; Burdick MD; Proost P; Van Damme J; Strieter RM
Circ Res; 2004 Oct; 95(9):855-7. PubMed ID: 15459074
[TBL] [Abstract][Full Text] [Related]
6. CXCL4L1 and CXCL4 signaling in human lymphatic and microvascular endothelial cells and activated lymphocytes: involvement of mitogen-activated protein (MAP) kinases, Src and p70S6 kinase.
Van Raemdonck K; Gouwy M; Lepers SA; Van Damme J; Struyf S
Angiogenesis; 2014 Jul; 17(3):631-40. PubMed ID: 24469069
[TBL] [Abstract][Full Text] [Related]
7. Expression of angiostatic platelet factor-4var/CXCL4L1 counterbalances angiogenic impulses of vascular endothelial growth factor, interleukin-8/CXCL8, and stromal cell-derived factor 1/CXCL12 in esophageal and colorectal cancer.
Verbeke H; De Hertogh G; Li S; Vandercappellen J; Noppen S; Schutyser E; El-Asrar AA; Opdenakker G; Van Damme J; Geboes K; Struyf S
Hum Pathol; 2010 Jul; 41(7):990-1001. PubMed ID: 20334899
[TBL] [Abstract][Full Text] [Related]
8. The Chemokine Platelet Factor-4 Variant (PF-4var)/CXCL4L1 Inhibits Diabetes-Induced Blood-Retinal Barrier Breakdown.
Abu El-Asrar AM; Mohammad G; Nawaz MI; Abdelsaid M; Siddiquei MM; Alam K; Van den Eynde K; De Hertogh G; Opdenakker G; Al-Shabrawey M; Van Damme J; Struyf S
Invest Ophthalmol Vis Sci; 2015 Feb; 56(3):1956-64. PubMed ID: 25711636
[TBL] [Abstract][Full Text] [Related]
9. Platelet factor-4 (CXCL4/PF-4): an angiostatic chemokine for cancer therapy.
Wang Z; Huang H
Cancer Lett; 2013 May; 331(2):147-53. PubMed ID: 23337289
[TBL] [Abstract][Full Text] [Related]
10. PF-4var/CXCL4L1 predicts outcome in stable coronary artery disease patients with preserved left ventricular function.
De Sutter J; Van de Veire NR; Struyf S; Philippé J; De Buyzere M; Van Damme J
PLoS One; 2012; 7(2):e31343. PubMed ID: 22384011
[TBL] [Abstract][Full Text] [Related]
11. CXCL4L1 inhibits angiogenesis and induces undirected endothelial cell migration without affecting endothelial cell proliferation and monocyte recruitment.
Sarabi A; Kramp BK; Drechsler M; Hackeng TM; Soehnlein O; Weber C; Koenen RR; Von Hundelshausen P
J Thromb Haemost; 2011 Jan; 9(1):209-19. PubMed ID: 20961394
[TBL] [Abstract][Full Text] [Related]
12. Cancer CXC chemokine networks and tumour angiogenesis.
Strieter RM; Burdick MD; Mestas J; Gomperts B; Keane MP; Belperio JA
Eur J Cancer; 2006 Apr; 42(6):768-78. PubMed ID: 16510280
[TBL] [Abstract][Full Text] [Related]
13. CXCL4 and CXCL4L1 in cancer.
Ruytinx P; Proost P; Struyf S
Cytokine; 2018 Sep; 109():65-71. PubMed ID: 29903575
[TBL] [Abstract][Full Text] [Related]
14. CXCL4 and CXCL4L1 Differentially Affect Monocyte Survival and Dendritic Cell Differentiation and Phagocytosis.
Gouwy M; Ruytinx P; Radice E; Claudi F; Van Raemdonck K; Bonecchi R; Locati M; Struyf S
PLoS One; 2016; 11(11):e0166006. PubMed ID: 27828999
[TBL] [Abstract][Full Text] [Related]
15. The control of angiogenesis and tumor invasion by platelet factor-4 and platelet factor-4-derived molecules.
Bikfalvi A; Gimenez-Gallego G
Semin Thromb Hemost; 2004 Feb; 30(1):137-44. PubMed ID: 15034805
[TBL] [Abstract][Full Text] [Related]
16. Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3.
Struyf S; Salogni L; Burdick MD; Vandercappellen J; Gouwy M; Noppen S; Proost P; Opdenakker G; Parmentier M; Gerard C; Sozzani S; Strieter RM; Van Damme J
Blood; 2011 Jan; 117(2):480-8. PubMed ID: 20980681
[TBL] [Abstract][Full Text] [Related]
17. Relative distribution and biological characterization of CXCL4L1 isoforms in platelets from healthy donors.
Ruytinx P; Janssens R; Berghmans N; Gouwy M; Ronsse I; Liekens S; Proost P; Van Damme J; Struyf S
Biochem Pharmacol; 2017 Dec; 145():123-131. PubMed ID: 28859966
[TBL] [Abstract][Full Text] [Related]
18. Angiostatic, tumor inflammatory and anti-tumor effects of CXCL4(47-70) and CXCL4L1(47-70) in an EGF-dependent breast cancer model.
Van Raemdonck K; Berghmans N; Vanheule V; Bugatti A; Proost P; Opdenakker G; Presta M; Van Damme J; Struyf S
Oncotarget; 2014 Nov; 5(21):10916-33. PubMed ID: 25373734
[TBL] [Abstract][Full Text] [Related]
19. PF-4/CXCL4 and CXCL4L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion.
Lasagni L; Grepin R; Mazzinghi B; Lazzeri E; Meini C; Sagrinati C; Liotta F; Frosali F; Ronconi E; Alain-Courtois N; Ballerini L; Netti GS; Maggi E; Annunziato F; Serio M; Romagnani S; Bikfalvi A; Romagnani P
Blood; 2007 May; 109(10):4127-34. PubMed ID: 17218382
[TBL] [Abstract][Full Text] [Related]
20. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
